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Abstract 
Tackling antimicrobial resistance (AMR) is particularly challenging in low-resource settings 
such as Fort Portal Regional Referral Hospital (FPRRH) in Western Uganda. Specific 
knowledge of local AMR epidemiology is required to inform evidence-based improvement of 
antibiotic stewardship measures in the hospital. To address this, we combined existing 
antimicrobial susceptibility testing (AST) from FPRRH, with whole genome sequencing (WGS) 
of 41 Staphylococcus aureus isolates (2017-2019). AST revealed 73% (30/41) of isolates were 
resistant to one or more antibiotics and 29% (12/41) were multi-drug resistant (MDR). 
Resistance phenotypes were largely explained by the presence of antibiotic resistance genes 
in WGS data.  Five isolates were methicillin-resistant S. aureus (MRSA) and MDR.  Although 
all isolates were susceptible to clindamycin, a 24% carriage of erm genes suggests potential 
for rapid development of resistance. We inferred a population structure for the S. aureus 
isolates by comparing their core genomes. Twenty isolates formed a tight cluster 
corresponding to multilocus sequence typing clonal complex (CC) 152, a CC found to be 
particularly prevalent in northern Africa. The frequency of genes associated with methicillin, 
chloramphenicol and ciprofloxacin resistance were significantly lower among CC152 strains 
than non-CC152 strains; thus, in keeping with previous work, we find that CC152 is almost 
exclusively methicillin-sensitive S. aureus (MSSA). Also, in agreement with other studies, we 
observed that the occurrence of Panton-Valentine leukocidin toxin-encoding genes was 
significantly higher among CC152 strains than non-CC152 strains. However, we also 
observed that the coagulase gene was over-represented in this CC, further defining the 
virulence strategy of this important pathogen. By generating detailed information about the 
epidemiology of circulating S. aureus and their antibiotic susceptibility, our study has 
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provided, for the first time, data on which evidence-based infection and AMR interventions 
at FPRRH can be based. 
Introduction  
The burden of antimicrobial resistance (AMR) is most keenly felt in low resource settings, 
where infection control measures are limited and access to antibiotics is intermittent in 
terms of both availability and type [1]. In Uganda, bacterial infections are responsible for 
>37% of hospital admissions and despite major international investments in healthcare 
systems, 90-161 deaths per 100,000 population are caused by infectious disease compared 
to <38 per 100,000 across the developed world [2]. Inappropriate prescribing, dispensing 
and administration of antibiotics are likely to contribute to this excess by compromising 
their utility and increasing the risk of adverse drug reactions and antibiotic resistance [2-6].  
Study on the emergence and epidemiology of AMR in S. aureus and spread of methicillin 
resistant S. aureus (MRSA) in Sub Saharan Africa (SSA) has intensified [7, 8] but data from 
resource-poor regions remain sparse. In Uganda, AMR phenotyping of S. aureus strains 
derived from symptomatic and apparently healthy humans and livestock has suggested that 
resistance to different and multiple antibiotics, including methicillin is prevalent [9-11]. 
The Ugandan National Action Plan (UNAP) 2018 was developed to address the high 
prevalence of AMR infections that restrict treatment options across the country. Better 
surveillance of AMR is a specific objective of the UNAP to strengthen the evidence base for 
policies on optimal use of antibiotics to preserve their efficacy [6]. The 2017 Joint External 
Evaluation noted that 25 healthcare facilities are now regularly performing antimicrobial 
susceptibility testing (AST) in Uganda [12]. However, as these facilities primarily lie in the 
more heavily populated areas of the country, most AMR surveillance has focused on them 
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(e.g., Kampala [13, 14], Mbarara [15] and Gulu [16]) rather than the more remote, rural 
settings in which, according to World Bank figures, 76% of the population live [17]. A 2018 
study identified spread of antibiotic-resistant Escherichia coli bacteria between people, 
livestock in rural Western Uganda, highlighting the need for further study [18]. 
To assist capacity in laboratory testing around the UNAP, the Ugandan Ministry of Health 
and Infectious Diseases Institute (IDI) have recently equipped the Fort Portal Regional 
Referral Hospital (FPRRH) with a microbiology laboratory capable of routine bacterial 
identification and AST. FPRRH serves the rural region of Kabarole, in the West of Uganda, 
near the border with the Democratic Republic of Congo, which is one such area where little 
data on AMR have been published. 
Investigation into the genetic basis of antibiotic resistance and the molecular epidemiology 
of antibiotic resistant bacteria is needed to gain a deeper understanding of the drivers of 
resistance spread. PCR-based assays have been used to explore of presence/absence of 
AMR- and virulence-associated genes among Ugandan S. aureus isolates [9, 13, 19], while 
spa (and SCCmec for MRSA) typing has been used to provide an epidemiological context [9, 
10, 13, 19-21]. These tools, however, have limited sensitivity; meanwhile advancements in 
rapid and affordable DNA sequencing technologies, and concurrent improvements of tools 
to predict AMR in silico, have led to improvements in diagnostic microbiology and studies of 
AMR [22]. 
This study is part of a multi-disciplinary intervention at FPRRH linking laboratory testing with 
training of health professionals in understanding common drivers of AMR aiming to reduce 
unnecessary and ineffective use of antibiotics in line with the UNAP [23]. We combine 
existing hospital AST data with whole genome sequencing to investigate antibiotic 
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resistance profiles, population structure and virulence gene carriage of S. aureus isolated 
from a range of infection sites including wounds, blood, and the urinary tract, in a region 
with little previous published data, towards better informed treatment practice and 
infection/AMR control policies. 
Materials and Methods 
Bacterial isolation and identification: S. aureus isolates were routinely collected and 
phenotypically characterised by the FPRRH microbiology laboratory between 2017 and 
2019. These isolates were primarily derived from skin wounds or suspected urinary tract or 
bloodstream infections. Bacteria were isolated and sub-cultured onto either blood agar, 
MacConkey agar and chocolate agar (Oxoid) at 37 °C (24-48 h). Putative S. aureus isolates 
were confirmed by Gram staining followed by a positive catalase and Staphaurex latex 
agglutination test (Thermo Fisher Scientific). All isolates were stored at -80°C. Sample 
metadata are available in Supplementary Data 1. 
Antibiotic Susceptibility Testing: For each isolate, a single colony was isolated and sub-
cultured, prior to screening by a disk diffusion assay according to EUCAST guidelines [24]. 
Susceptibility to eight different antibiotics belonging to different classes was tested: 
cefoxitin (30μg), a second-generation cephalosporin used to indicate MRSA; ciprofloxacin 
(5μg), a fluoroquinolone; cotrimoxazole (sulfamethoxazole - trimethoprim (1.2μg and 
23.75μg respectively)); tetracycline (30μg); erythromycin (15μg), a macrolide and 
clindamycin (2μg), a lincosamide; gentamycin (10μg), an aminoglycoside; and 
chloramphenicol (30μg) (Oxoid). 
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DNA Extraction and Quality Control: Bacterial cultures were grown in Luria Bertani (LB) 
broth for 18-24h at 37 °C and DNA was extracted using the Isolate II Genomic DNA Kit 
(Bioline, UK) according to the manufacturer’s instructions, including the extra lysozyme pre-
treatment step for efficient lysis of Gram-positive cells. DNA concentration and purity were 
measured using the Qubit 3.0 Fluorometer (Thermo Fisher Scientific) with Quant-iT dsDNA 
Assay Kit, High Sensitivity (Invitrogen). DNA library quality control was performed using a 
Tapestation 2200 with a High Sensitivity D1000 kit (Agilent Technologies) according to the 
manufacturer’s instructions. 
Whole Genome Sequencing, Draft Genome Assembly and Analysis: Whole genome DNA 
libraries were prepared using the Nextera XT library preparation kit according to the 
manufacturer’s instructions. Samples were multiplexed on a single MiSeq flowcell using 
Nextera XT barcodes and normalised using the bead-based normalisation kit (Illumina). 
Sequencing of 41 pooled genomes was performed simultaneously at Makerere University, 
Uganda and the University of Salford, UK, as part of a training activity to support UNAP AMR 
initiatives. In both cases, DNA sequencing was performed using a MiSeq v2 500 cycle kit 
(2x250bp reads; Illumina). Raw reads were trimmed using fastq-mcf and assembled using 
SPADES v3.9.1 [25]. The resulting draft assemblies were annotated using PROKKA v 1.13.3 
[26].  
The online webtool PathogenWatch (https://pathogen.watch) was used to cluster the 
annotated genomes of each isolate to predict antibiotic resistance profiles. PathogenWatch 
uses PAARSNP, bespoke software that uses BLAST against a custom database (combined 
from public AMR databases such as CARD, ResFinder and NCBI) to highlight the presence or 
absence of genes and SNPs implicated in antimicrobial resistance and infers their combined 
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effect. Chloramphenicol resistance was predicted by CARD (Staphylococcus intermedius 
chloramphenicol acetyltransferase) analysis [27] implemented in ABRICATE 
(https://github.com/tseemann/abricate). Virulence gene presence was also predicted using 
ABRICATE, against the VFDB database [28]. Multi-locus sequence types (MLST) were 
confirmed against the pubMLST database [29] using the software “MLST” 
(https://github.com/tseemann/mlst). Core genome alignment was ascertained by SNIPPY 
[30], and a phylogenetic tree generated by FastTree using a GTR+CAT model of nucleotide 
evolution [31] (Figure 1). Additional genomic analyses were performed using ABRICATE and 
ROARY [32]. 
Univariant statistical analysis of antimicrobial resistance and virulence gene 
presence/absence was performed in Minitab.    
Results & Discussion 
Antibiotic susceptibility testing (AST) at FPRRH: This study reviewed the antibiotic 
resistance profiles of 41 S. aureus isolates determined by disk diffusion assay as part of the 
routine laboratory diagnostic service at FPRRH, Uganda (Figure 1). Overall, 73% of S. aureus 
isolates (30/41) were resistant to one or more antibiotics. 32% (13/41) were resistant to one 
antibiotic, most commonly tetracycline, and a further 41% (17/41) were resistant to two or 
more antibiotics, most commonly including cotrimoxazole and tetracycline. 24% of isolates 
(10/41) were classified as multi-drug resistant (MDR), exhibiting resistance to antibiotics 
belonging to three or more classes [33]. 5% (2/41) were resistant to antibiotics belonging to 
six different classes, and thus considered pan resistant. These levels of resistance and MDR 
are not unexpected; for example, Seni and colleagues [9] reported 21% of Gram-positive 
isolates from surgical site wounds of patients in Mulago Hospital, Kampala (Uganda) were 
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MDR, whereas Kateete and colleagues [34] observed 31% of S. aureus isolates recovered 
from nasopharyx of children in rural Eastern Uganda were MDR. A study of post-operative 
sepsis cases in rural Eastern Uganda [35] reported 14% S. aureus isolates to be resistant to 
five different classes of antibiotics and 3% resistant to six different classes [35]. Whilst the 
Ugandan national action plan (UNAP) reports prevalence of MRSA in healthcare settings at 
2-50% [23], the WHO AMR global report on surveillance (2014) found overall MRSA 
prevalence to range from 12-80% across Africa and to exceed 20% in all six WHO regions 
[36]. There have been reports of more than 80% MRSA prevalence in African, American and 
Western Pacific regions [36].  
Empirical treatment (ceftriaxone + metronidazole) is prescribed for suspected infections at 
FPRRH. Whilst metronidazole covers anaerobic bacteria, ceftriaxone is a broad-spectrum 
cephalosporin that is well tolerated and commonly used to effectively treat infections 
caused by most aerobes including methicillin susceptible S. aureus (MSSA). Cefoxitin 
susceptibility testing was used as a proxy to indicate resistance to ceftriaxone and identify 
MRSA. However, limited resources at FPRRH prevented a considerable number of isolates 
from being tested. Of 13 isolates tested, five (38%) were resistant (MRSA), a prevalence akin 
to previous Ugandan studies [9, 16, 35]. All five MRSA isolates were MDR; Kateete and 
colleagues [13] also observed markedly higher rates of MDR among MRSA strains compared 
to MSSA strains. The observed frequency of MRSA at FPRRH suggest a potentially high level 
of failure of the empirical treatment, and the need for informed decisions about 
procurement of alternative antibiotics. 
Whole genome sequencing data: Draft whole genomes were generated for all 41 S. aureus 
isolates using Illumina MiSeq data. All sequence read data used for genome assembly, 
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annotation and AMR genotype prediction are available on the European Nucleotide Archive 
under project accession: PRJEB40863. According to PathogenWatch (data available at [37]), 
we identified between 86% to 100 % of the core gene families for all isolates (mean 95% per 
isolate). N50 ranged from 3,045 bp to 145,228 bp (mean 26.8 Kbp; See Supplementary Data 
1).  
Genomic correlation with phenotypic AMR profiles: Although the primary aim of this study 
was to predict antibiotic resistance data for S. aureus isolates for which phenotype data was 
lacking due to poor resources, the study provides an opportunity to correlate AMR 
phenotype with genotype prediction. A recent study of 778 MRSA isolates from the UK, 
comparing Illumina WGS data – based analysis with disc diffusion AST data showed 99.7% 
accuracy [38]. To that end, we have compared AST results from FPRRH with antibiotic 
resistance gene (ARG) presence/absence data drawn from WGS. Genetic markers of 
resistance were found in all 11 (27%) isolates that were reported as susceptible to all the 
antibiotics tested for at FPRRH.  Phenotypic and genotypic predictions of susceptibility to 
each antibiotic were compared in turn (Figure 1 and Supplementary Data 1).  
Tetracycline resistance was the most common phenotype found in 56% of isolates tested 
(19/34). Previously, prevalence of tetracycline resistance in Uganda has been reported as 
high as 55% among clinical isolates [39] and 68% among environmental/carriage isolates 
[13]. Tetracycline resistance was accounted for in 67% (12/18) of genomes by the presence 
of tetK/M (encoding an efflux pump and ribosomal protection respectively). However, no tet 
genes were found in the genomes of seven tetracycline resistant isolates. Tetracycline 
susceptibility was predicted (by absence of tetK/M genes) for 93% of the susceptible isolates 
tested (14/15). Tetracycline resistance correlation between WGS and AST data has been 
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reported as high as 100% [38]. Others report 83% correlation of resistance phenotypes with 
presence of tetK and tetM genes [40]. Although tetracycline dispensing for these infection 
types has not been reported at FPRRH, it is commonly used in treatment of Ugandan 
livestock, as a broad-spectrum antibiotic, antiparasitic and as a growth supplement [41]. 
Nevertheless, resistance levels in livestock in western Uganda have been reported as low as 
8% [42] or 12% [41], implying possible widespread but unrecognised dispensing of this 
antibiotic to humans [43]. 
Of 37 isolates tested 16 (43%) were resistant to cotrimoxazole (trimethoprim + 
sulfamethoxazole) and a further 5 (14%) showed an intermediate result. However, the 
remaining 16 (43%) were susceptible despite genetic indicators of trimethoprim resistance 
(dfrG/dfrA) present in almost all isolates (98%, 40/41). Others have reported trimethoprim 
resistant phenotypes where isolates were genotypically predicted to be susceptible, in one 
case despite the presence of a dfrA gene, suggesting that in silico prediction of trimethoprim 
resistance may require further work [38, 44].  
Increasing levels of dfrG-related trimethoprim resistance were reported in 2014, suggesting 
that resistance would soon be widespread in Africa through imported infections [45]; This 
study would suggest that in the prevailing six years, this prediction has come to pass, but 
does not reflect the much higher resistance rates reported elsewhere in Uganda [8, 9, 13, 
16, 46]. This may have been driven, in part, by the widespread use of cotrimoxazole for 
prophylaxis against secondary infections in HIV positive patients across SSA [47, 48] and 
highlights the need for wider study and control of other antibiotics showing decreased 
efficacy. 
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AST suggested that 71% of isolates (29/41) were susceptible to erythromycin and these 
phenotypes matched the genotype in most cases (26/29). Thirteen isolates (32%) were 
found to be resistant to erythromycin, which is considerably lower than reported by several 
other Ugandan studies [35, 46, 49, 50]  and all erythromycin-resistant isolates were 
susceptible to clindamycin. For some isolates, this could be explained by the presence of an 
inducible efflux pump gene (msrA), which is implicated in resistance to erythromycin [51]. 
More commonly, resistance to both these antibiotic groups is partly predicted by the 
presence of erm genes, the products of which modify the ribosomal target site to prevent 
antibiotic binding. Erythromycin resistance (predicted by PathogenWatch by detection of 
ermA (1/41), ermC (11/41) or msrA (5/41) genes) did not always correlate with phenotype: 
38% (5/13) of resistant isolates were not predicted by genotype. In contrast, 100% of 
isolates tested (35/35) appeared susceptible to clindamycin despite detection of ermA or 
ermC in 12 isolates. This suggests that the genes are under erythromycin-inducible 
regulation, but that exposure to clindamycin in vivo could select for constitutive expression 
mutants, that would confer resistance to both [52]. According to the WHO essential 
medicines list (2019), clindamycin is an access antibiotic recommended as a second choice 
for bone / joint infections. Clindamycin has not been used at FPRRH but has been used 
elsewhere in Uganda; a 2014 study based at Mbarara Regional Referral Hospital in 
Southwestern Uganda reported 36% of isolates as clindamycin-resistant and also showed 
discrepancies between phenotypes and genotypic prediction [49].  Clindamycin resistance 
rates of 0-59% have been reported elsewhere in Uganda between 2009-2018 [46] and was 
reported as early as 2008 in Tanzania [53]. It is therefore clear that 
erythromycin/clindamycin resistance is a complex issue that requires ongoing monitoring 
given the potential to expanded resistance. 
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Other options from the WHO list of access antibiotics include gentamycin and 
chloramphenicol, which are often recommended when empirical treatments fail [46]. 
Gentamycin is a commonly used aminoglycoside at FPRRH; 17% of isolates (7/41) were 
gentamycin resistant, but specific aminoglycoside resistance genes (apH3 and aacA-aphD) 
were only found in 4 (of 41) genomes. Similar resistance rates have been reported in 
Kampala [9] and Gulu [16], but others report much higher rates [46]. 
Aminoglycoside resistance is complex, and conflicts between genotype and phenotype have 
been previously reported [54], but may also be representative of the short read sequencing, 
which could be clarified using long-read technologies or complementary techniques. 
Phenotypic and genotypic analysis of chloramphenicol susceptibility were largely in 
agreement, with 97% of isolates being susceptible to chloramphenicol (36/37) CARD analysis 
predicted only one isolate (sample 149) to be resistant, which did not correlate with several 
other studies from Mulago hospital, Kampala that suggest much higher rates of 
chloramphenicol resistance ranging between 14% and 88% [9, 13, 14, 46, 50].   
Ciprofloxacin (a fluoroquinolone) and ceftazidime (a third-generation cephalosporin) both 
appear on the WHO watch list of essential antibiotics that are considered at high risk of 
selecting for further bacterial resistance, and should be prioritised for stewardship 
programmes [2]. A total of 24% (10/41) of S. aureus isolates at FPRRH were resistant to 
ciprofloxacin, and two more exhibited intermediate resistance; 75% of these correlated with 
genotypic prediction with mutations in gyrA and grlA genes. Ciprofloxacin resistance in S. 
aureus is known to develop rapidly through single nucleotide mutations [55], and rates vary 
across other Ugandan studies, most of which report higher rates of ciprofloxacin resistance 
than at FPRRH  [9, 14, 16, 46]. 
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Phenotypic resistance to cefoxitin, as a proxy for ceftazidime resistance and MRSA 
corresponded to genotypically-predicted methicillin resistance, with one susceptible isolate 
being predicted to be resistant. Of note, stocks of cefoxitin disks were poorly maintained at 
FPRRH during the study period and 28 isolates were not able to be tested. Of 13 isolates 
tested, five (38%) were resistant (MRSA). In contrast to the rates of resistant isolates to 
other antibiotics, the percentage of MRSA at FPRRH is similar or higher than those reported 
elsewhere (Kampala: 37.5% [9], 29% [46] and 28% [39]; Mbale: 27% [35] and Gulu: 22% 
[16]). All five MRSA isolates from FPRRH were MDR. 14% (4/28) of isolates that were not 
tested harboured mecA, a clear genetic indicator of MRSA. The majority (71%) of isolates 
(30/41) also harboured the blaZ gene which encodes a β-lactamase conferring resistance to 
a range of penicillins and other β-lactam antibiotics. Two such isolates remained susceptible 
to ciprofloxacin, which could be recommended as an alternative treatment in these cases. 
Overall, the WGS data provided a more detailed view of the AMR mechanisms circulating in 
S. aureus-associated infections at FPRRH although susceptibility was more commonly 
predicted than resistance. Given the non-contiguous nature of the draft genomes this could 
be due to a lack of complete gene coverage enabling confident prediction of gene presence 
or absence. Complete genomes, such as using PacBio or Oxford Nanopore sequencing would 
increase confidence in prediction, but the additional effort may not be cost-effective in low-
middle income resource settings. These data are nevertheless useful for in-filling missing 
information from AST data due to the poor supply of appropriate materials, towards 
informing more-effective treatment of S. aureus infections at FPRRH.   
Population structure of FPRRH S. aureus isolates: domination of MSSA CC152: We 
observed marked diversity among the 41 S. aureus isolates we characterised, as quantified 
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in a core genome phylogeny (Figure 1). We were able to obtain complete MLST data for 25 
of these (Figure 1) and delineated nine different STs belonging to six CCs. Isolates belonging 
to a particular CC clustered together in the population structure inferred from core genome 
comparison (Figure 1). Most isolates for which we obtained complete MLST data (15) 
belonged to ST152 and its single locus variant ST1633 (CC152). For three more isolates, we 
obtained MLST data for 6 out of 7 loci allowing them to be attributed to CC152 if not a 
specific ST. Two further isolates (180 and 191) had more incomplete MLST data, but core 
genome analysis indicated they clustered tightly with CC152 isolates. Thus, in total 20 of the 
41 isolates we studied (49%) were likely CC152. Ruimy and colleagues [56] were the first to 
highlight the exceptionally high frequency of CC152 in northern Africa, having assigned 24% 
of isolates recovered from the nasopharynx of apparently healthy Malian people to this CC. 
Numerous subsequent studies of clinical isolates across the continent have supported this 
observation (reviewed in [57]); most recently, Kyany’a et al (2020) and Obasuyi et al (2020) 
reported CC152 was the most common clonal complex encountered, representing about a 
quarter of the clinical isolates they characterised in Kenya and Nigeria respectively [58, 59].  
A high proportion of CC152 isolates had either no resistance phenotype or were resistant to 
just one antibiotic (most commonly tetracycline).  25% were resistant to cotrimoxazole and 
20% were resistant to erythromycin. The most common ARGs in this group were dfrA/dfrG 
(100%), blaZ (80%) and tet (40%). Phenotypic and genotypic screening determined low 
frequencies of resistance to ciprofloxacin, clindamycin and chloramphenicol. Comparison of 
CC152 and non-CC152 isolates in this study revealed PathogenWatch predictions of 
methicillin, chloramphenicol and ciprofloxaxin resistance were all significantly less prevalent 
in CC152 members (χ
2
 =7.96, 4.39 and 7.00, P=0.005, 0.036 and 0.008 respectively). 
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PathogenWatch also predicted that resistance-associated mecA (methicillin resistance), grlA 
and gyrA (ciprofloxacin resistance) were significantly less prevalent among CC152 members 
(χ
2
 =7.96, 5.42 and 5.63, P=0.005, 0.020 and 0.018 respectively). Thus 19/20 (95%) of CC152 
isolates were MSSA. In contrast to other CC152 members, three isolates exhibited MDR 
phenotypes. Isolates 145, 175 and 191 were resistant to 3, 4 and 5 classes of antibiotics 
respectively, however, there was little similarity in their resistance profiles and ARG 
compliments, suggesting that they were acquired independently of one another. Isolate 191 
was the only MRSA and harboured genetic markers of resistance to eight different classes of 
antibiotic. All three MDR isolates were resistant to erythromycin, but associated genetic 
markers were only present in 191, harbouring both erm and msrA genes that are commonly 
plasmid associated. Further investigation is needed to determine how these MDR and 
potentially pan-resistant profiles have developed in a clonal complex that is mainly 
associated with healthy individuals.  
FPRRH S. aureus CC152 isolates possess a specific virulence gene repertoire: Given the 
frequency with which CC152 strains were encountered, we explored variation in virulence-
associated gene content between isolates belonging to this clonal complex (n = 20) and 
those that did not (n = 21). The majority of virulence-associated genes were neither over- 
nor under-represented among CC152 stains, but there were a handful of exceptions. Genes 
that were significantly more common among CC152 strains included lukF-PV and lukR-PV 
that encode the two subunits of the Panton–Valentine leukocidin (PVL) cytotoxin (χ
2
 =20.74, 
P <0.001 and χ
2
 =18.09, P<0.001 respectively) and coa, that encodes a coagulase (χ
2
 = 13.82, 
P<0.001). An association between CC152 and PVL has been noted previously [56]. Coa is a 
long-established virulence factor of S. aureus that is able to induce blood coagulation by 
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interacting with fibrinogen and prothrombin [60]. Interestingly, von Willebrand factor 
binding protein, encoded by vWbp, exhibits multiple similarities in terms of coagulation 
induction function to Coa [60]. That vWbp is absent from CC152 isolates, but present in 
about 37% of non-CC152 isolates (χ
2 
=9.47, P=0.002) may point to the two proteins fulfilling 
similar roles in different S. aureus lineages. Several other virulence factor-encoding genes 
were encountered significantly less frequently among CC152 isolates than non-CC152 
isolates. These included genes encoding (i) the chemotaxis inhibitory protein Chp (χ
2
 =7.96, 
P=0.005), (ii) the adhesin Map (χ
2
=12.60, P=0.003), the serine-aspartate repeat protein SdrC 
that is associated with biofilm formation (χ
2
=16.79, P<0.001), and the Sec enterotoxin (χ
2
= 
5.42, P=0.020). The EsaG protein is thought to serve as an anti-toxin in the Ess Type 7 
secretion system of S. aureus [61]. Multiple genes encoding EsaG have been encountered in 
S. aureus genomes and we observed significant variation in their presence/absence among 
CC152 members and other isolates, such that some copies (esaG1, esaG3, and esaG4) were 
under-represented (χ
2
= 11.11, 9.48, 12.60, P <0.001, 0.002, <0.001 respectively) among 
CC152 strains whereas others (esaG5, esaG7 and esaG8) were over-represented (χ
2
= 8.84, 
5.03, 6.55, P= 0.003, 0.025, 0.010 respectively). The significance of this is unclear as the role 
of different copies is unknown. 
Conclusions 
The main goal of this study, in keeping with the UNAP, was to create local knowledge of 
circulating AMR in disease-associated S. aureus, to strengthen the evidence base for policies 
on optimal use of antibiotics to preserve their efficacy, and through which we could inform 
treatment policy at FPRRH and its surrounding catchment area. Key findings include the 
incidence of MDR and pan-resistant isolates, the prevalence of PVL and coagulase-carrying 
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CC152 strains in a clinical setting, and the apparent low frequency of resistance to 
clindamycin and chloramphenicol compared to other regions of Uganda. 
The resistance profiles observed in this study were largely similar to those described 
elsewhere in Uganda. Nevertheless, the largest discrepancies between this and other 
studies were the universal susceptibility to clindamycin at FPRRH, whilst a relatively high 
41% resistance was found at Mulago, and for trimethoprim (43% in this study, and ≥89% in 
Mulago), and chloramphenicol, for which although rates of resistance vary between 14% - 
88% elsewhere [9, 13, 14, 46, 50], FPRRH strains were almost all susceptible. National advice 
on control strategy based on national clinical guidelines, or data that may be focused upon 
major urban centres, are not always aligned with antibiotic susceptibility observed at the 
local level, emphasising the requirement for local knowledge such as that described here 
[16].  
It is clear that procurement of sufficient materials to perform AST tests for resistances 
identified in the antibiogram, supported by molecular data, will be important for robust 
future surveillance to inform effective treatment and to ensure a rapid, appropriate planned 
response to treatment failures. Given the frequent circulation of S. aureus isolates between 
community and hospital settings [62], and combined with the variability in resistance rates 
across Ugandan studies this further highlights the need for continued, robust epidemiology 
at the local level to inform policy on control strategies that can minimise treatment failures 
and the spread of antimicrobial resistance. 
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Figure 1: Core genome phylogeny of 41 Staphylococcus aureus isolates from Fort Portal 
Regional Referral hospital isolated between 2017 and 2019, aligned against the NCTC 
8325 reference genome [63]. Tree is displayed alongside antibiotic sensitivity data 
(coloured black circles represent presence, empty circles represent absence, no circle 
represents no data available); Genotypic antibiotic resistance predictions by 
PathogenWatch, (coloured squares represent presence of AMR SNP (Ciprofloxacin) or 
genes (others). For AMR genes shapes represent presence of antibiotic genes / SNP, 
according to class.  The core genome was generated by SNIPPY [30], and the tree file 
generated using FastTree [31] using a generalized time-reversible (GTR+CAT) model of 
nucleotide evolution. Also shown are sample ID, Sequence Type (predicted by pubMLST 
[29]). Virulence gene presence (VFDB) is displayed as grey circles. Further sample 
metadata can be found in Supplementary Data 1.  
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